This review provides a comprehensive overview of the pharmacological properties and analytical determination techniques for the antianginal drug trimetazidine.
May support trimetazidine in stable angina; leaves open need for updated RCTs versus modern therapies.
Trimetazidine (TMZ) is an effective and well-tolerated antianginal drug that possesses protective properties against ischemia-induced heart injury. Growing interest in metabolic modulation in recent years urged an up-to-date review of the literature on TMZ. This review consists of two major sections: (1) comprehensive and critical information about the pharmacological effects, mechanism of action, pharmacokinetics, side effects, and current usage of TMZ, and (2) developments in analytical techniques for the determination of the drug in raw material, pharmaceutical dosage forms, and biological samples.
No takes yet. Share an insight, caveat, or question.
Onay-Beşi̇kçi̇ et al. (2008) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: